Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.78)
# 700
Out of 4,944 analysts
482
Total ratings
42.23%
Success rate
10.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $17.41 | +72.31% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.63 | +1,800.24% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $4.25 | +1,664.71% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $14.89 | +302.96% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $3.32 | +125.90% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $3.67 | +254.22% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $3.77 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.42 | +1,327.55% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $7.44 | +841.49% | 6 | Mar 31, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $1.91 | - | 13 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $23.91 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $4.44 | +5,311.50% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.68 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $9.55 | +235.08% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $62.00 | -43.55% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $48.03 | +56.15% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $9.04 | +132.30% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $64.72 | +11.25% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $359.00 | +12.81% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.60 | -1.79% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $28.11 | +237.96% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $6.85 | +162.77% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.79 | +243.01% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.40 | +47.28% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $25.00 | +92.00% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $6.53 | +14.85% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.77 | +546.83% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $11.32 | +14.84% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.46 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $21.14 | +18.26% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.42 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.69 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $39.86 | -82.44% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $37.87 | -44.55% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.51 | - | 2 | Feb 15, 2017 |
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $17.41
Upside: +72.31%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.63
Upside: +1,800.24%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $4.25
Upside: +1,664.71%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $14.89
Upside: +302.96%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $3.32
Upside: +125.90%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $3.67
Upside: +254.22%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $3.77
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.42
Upside: +1,327.55%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $7.44
Upside: +841.49%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.91
Upside: -
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $23.91
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $4.44
Upside: +5,311.50%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.68
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $9.55
Upside: +235.08%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $62.00
Upside: -43.55%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $48.03
Upside: +56.15%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $9.04
Upside: +132.30%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $64.72
Upside: +11.25%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $359.00
Upside: +12.81%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.60
Upside: -1.79%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $28.11
Upside: +237.96%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $6.85
Upside: +162.77%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.79
Upside: +243.01%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.40
Upside: +47.28%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $25.00
Upside: +92.00%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $6.53
Upside: +14.85%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.77
Upside: +546.83%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $11.32
Upside: +14.84%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $21.14
Upside: +18.26%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $25.69
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $39.86
Upside: -82.44%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $37.87
Upside: -44.55%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.51
Upside: -